The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 939-945

  Van Den Bemt, Bart J F ^a   Den Broeder, Alfons A ^a   Wolbink, Gert Jan ^c   Van Den Maas, Aatke ^a   Hekster, Yechiel A ^b   Van Riel, Piet L C M ^b   Benraad, H Bart ^a   Van Den Hoogen, Frank H J ^a  

^a Sint Maartenskliniek ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

infliximab; infliximab trough concentrations; prediction response; rheumatoid arthritis

Indexed keywords

FOLIC ACID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; YOUDEN INDEX;

INFLIXIMAB; INFLIXIMAB TROUGH CONCENTRATIONS; PREDICTION RESPONSE; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888065488     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12142     Document Type: Article

References (21)

1. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-3443.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P,. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
4. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P,. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008; 47: 495-499.
5. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL,. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 2011; 30; 13: R126.
6. Emery P, Dörner T,. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011; 70: 2063-2070.
7. Gülfe A, Kristensen LE, Geborek P,. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009; 36: 517-521.
8. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T,. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-3789.
9. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B,. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-715.
10. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K,. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-1745.
11. Svenson M, Geborek P, Saxne T, Bendtzen K,. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-1834.
12. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C,. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-178.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
14. van Gestel AM, Haagsma CJ, van Riel PL,. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-1850.
15. Van den Bemt BJF, Van Eerd JE, Den Broeder AA, Hekster YA, Van Riel PLCM, Stapel SO, Wolbink GJ,. Validation of a precise and accurate enzyme-linked immunosorbent assay for the bioanalysis of infliximab in human serum. 2009. In: Optimizing Pharmacotherapy in Patients with Rheumatoid Arthritis (Thesis). Nijmegen: 62-71.
16. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B,. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-715.
17. Youden WJ,. Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
18. Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J,. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009; 68: 1285-1289.
19. van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH,. Sustained effect after lowering high dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008; 67: 1697-1701.
20. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
21. Isaacs JD, Ferraccioli G,. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011; 70: 4-7.